The FDA has officially removed semaglutide and tirzepatide from its drug shortage list — and enforcement against compounding pharmacies is accelerating. Here's what your pharmacy needs to know about compliance, liability exposure, and insurance right now.
Dean Hamid, CLCS, AINS
PRIA Brokers — Peptide Insurance Specialist
As of early 2026, the FDA has officially removed semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from its drug shortage list. For the compounding pharmacy industry, this is not just a supply chain update — it's a regulatory turning point with serious insurance and liability consequences.
Compounding pharmacies that have been operating under shortage exemptions are now facing hard enforcement deadlines. The FDA has made its position clear: mass-compounded copies of FDA-approved GLP-1 medications are no longer permitted under the shortage exemption, and the agency intends to take action against non-compliant operations.
If your pharmacy is still compounding semaglutide or tirzepatide at scale, your insurance situation just became significantly more complicated.
The FDA's enforcement timeline has moved quickly:
**503B outsourcing facilities** faced an initial enforcement deadline of February 18, 2025 (subject to ongoing court proceedings)
**503A compounding pharmacies** faced a deadline of April 22, 2025
By early 2026, the FDA is actively pursuing action against companies mass-marketing non-FDA-approved compounded GLP-1 drugs — including high-profile telehealth platforms
The agency has specifically signaled intent to remove GLP-1 APIs from the 503B bulks list, citing resolved shortages and the absence of clinical necessity for large-scale compounding.
When compounding pharmacies operated under the shortage exemption, their activity existed in a legally gray — but somewhat defensible — space. Carriers understood the regulatory context and could underwrite accordingly.
Now that the shortage has ended, pharmacies that continue mass-compounding GLP-1 peptides face a fundamentally different risk profile:
**1. Regulatory Defense Exposure Spikes**
FDA enforcement actions — warning letters, injunctions, seizures — are expensive to defend even when you ultimately prevail. Legal defense costs alone can run into six or seven figures. Most standard pharmacy policies do not cover FDA/FTC regulatory defense.
**2. Product Liability Claims Become Harder to Defend**
If a patient suffers an adverse event from a compounded GLP-1 medication made outside of shortage exemption, plaintiffs' attorneys will point directly to the FDA's public statements. The legal exposure is substantially higher than it was 18 months ago.
**3. Carriers Are Re-Underwriting the Space**
Multiple specialty carriers have begun re-evaluating their appetite for compounding pharmacy risks that include GLP-1 compounds. Some have added exclusions. Others are non-renewing policies. If you haven't reviewed your policy language recently, there may be exclusions you're unaware of.
This is the most urgent step. Pull your current general liability, product liability, and professional liability policies and look for:
Exclusions for FDA-regulated compounded medications
Exclusions tied to shortage exemptions that no longer apply
Regulatory defense coverage limits and scope
Whether your policy covers 503A vs. 503B operations specifically
Standard pharmacy policies are designed for dispensing, not manufacturing. Compounding pharmacies — especially those that have been producing GLP-1 compounds at scale — need:
**Product liability** that covers compounded formulations, not just dispensed branded drugs
**Regulatory proceedings coverage** for FDA warning letters, inspections, and enforcement actions
**Errors & omissions (E&O)** for professional liability tied to compounding decisions
**Product recall insurance** in case of a contamination event or FDA-mandated recall
Most standard policies provide none of these adequately.
Carriers underwriting compounding pharmacy risks in 2026 want to see:
SOPs for formulation and quality control
Evidence of compliance with state board requirements
Documentation of patient-specific prescriptions (for 503A)
Proof of FDA registration (for 503B)
Evidence that GLP-1 compounding has been wound down or is strictly patient-specific
Having this documentation ready can mean the difference between a competitive renewal and being non-renewed entirely.
The compounding pharmacy insurance market has changed materially in the past 12 months. A generalist broker placing coverage through standard pharmacy programs may not have access to the specialty markets that still underwrite GLP-1 compounding risk. And they may not know to ask the right underwriting questions.
A specialty broker with peptide and compounding pharmacy experience can:
Access carriers that still write this risk
Structure your coverage to avoid gaps
Help you understand what disclosures are required and how to present your risk favorably
The FDA ending the GLP-1 shortage is good news for patients who depend on brand-name semaglutide and tirzepatide. For compounding pharmacies, it's a regulatory reset that requires immediate action.
Your insurance program needs to reflect where the regulatory environment actually is — not where it was in 2024. If you haven't reviewed your coverage since the shortage ended, there's a real possibility you have gaps that wouldn't be discovered until you filed a claim.
**PRIA Brokers specializes in insurance for compounding pharmacies, peptide manufacturers, and GLP-1 businesses.** We work exclusively in this space and have access to specialty markets that provide the coverage your operation actually needs.
Call us at (888) 998-7742 or [request a quote](/contact) to review your current coverage and identify any gaps before your next renewal.
PRIA Brokers specializes in coverage for peptide manufacturers, GLP-1 compounders, distributors, and suppliers. Compare quotes from A-rated specialty carriers.